2021 and beyond with Destiny Pharma's CEO, Neil Clark & CFO Shaun Claydon
Management of (DEST ), the AIM listed infection prevention biotechnology company, offer an overview of the Company, their platform and their late stage clinical assets heading towards phase 3 trails. The team expand on the anti infective market, their COVID 19 program and the strength of their balance sheet. The Company finish with their expectations for 2022 and beyond.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.